8-K: Arcus Biosciences Announces Positive Interim Results for Colorectal Cancer Treatment

Arcus Biosciences reports statistically significant improvements in progression-free and overall survival in a Phase 2 trial for metastatic colorectal cancer using a combination therapy.

Summary

• Arcus Biosciences has released interim results from Cohort B of their Phase 1b/2 clinical trial, ARC-9, evaluating a combination therapy for third-line metastatic colorectal cancer.
• The study compared etrumadenant and zimberelimab combined with FOLFOX and bevacizumab (EZFB) against regorafenib.
• The results showed that EZFB significantly improved progression-free survival (PFS) and overall survival (OS) compared to regorafenib.
• The median follow-up was 20.4 months, and 112 patients were randomized in the study.
• The EZFB arm had a median PFS of 6.2 months compared to 2.1 months for regorafenib, with a hazard ratio of 0.27.
• The median OS was 19.7 months for EZFB compared to 9.5 months for regorafenib, with a hazard ratio of 0.37.
• The safety profile of EZFB was consistent with the known toxicities of FOLFOX and bevacizumab, with no treatment-related deaths in either arm.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with statistically significant improvements in both PFS and OS, indicating a strong potential for the drug combination. The safety profile is also acceptable, further boosting the positive sentiment.

Positives

• The combination therapy, EZFB, demonstrated a statistically significant improvement in both PFS and OS compared to regorafenib.
• The hazard ratios for both PFS (0.27) and OS (0.37) indicate a substantial reduction in the risk of disease progression and death.
• The safety profile of the EZFB combination was consistent with known toxicities, with no unexpected safety concerns.
• The study results suggest a potential new treatment option for patients with refractory metastatic colorectal cancer.

Negatives

• The EZFB combination includes FOLFOX and bevacizumab, which are known to have toxicities, although the study reported no unexpected toxicities.
• Grade 3 treatment-emergent adverse events were higher in the EZFB arm (82.4%) compared to the regorafenib arm (48.6%).
• Discontinuation of all study drugs due to treatment-emergent adverse events was higher in the regorafenib arm (17.1%) compared to the EZFB arm (5.4%).

Risks

• The study is an interim analysis, and further data may be needed to confirm these results.
• The EZFB combination includes multiple drugs, which may increase the complexity of treatment and potential for adverse events.
• The study population was limited to patients who had previously progressed on oxaliplatin and irinotecan, so the results may not be generalizable to all patients with metastatic colorectal cancer.

Future Outlook

The company plans to present the full results of the interim analysis at the ASCO Annual Meeting on June 2, 2024, and further investigation of the EZFB regimen is warranted given the clinically meaningful improvements in PFS and OS.

Management Comments

• The company plans to issue a press release on June 2, 2024 to announce the full results of the interim analysis presented at the ASCO Annual Meeting.

Industry Context

This announcement is significant in the field of oncology, particularly for metastatic colorectal cancer, where new treatment options are needed. The positive results of the EZFB combination therapy could potentially change the standard of care for patients who have progressed on prior treatments.

Comparison to Industry Standards

• Regorafenib is a standard treatment for third-line metastatic colorectal cancer, and the study results show that the EZFB combination significantly outperforms it.
• The hazard ratios for PFS (0.27) and OS (0.37) are very strong compared to typical results seen in this setting.
• Other companies such as Bayer (manufacturer of regorafenib) and various immunotherapy developers are active in this space, but the Arcus results are very promising.
• The results are comparable to or better than some other combination therapies being investigated for mCRC, suggesting a potential new standard of care.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with metastatic colorectal cancer may have a new treatment option with improved outcomes.
• Healthcare providers may consider incorporating the EZFB combination into their treatment protocols.

Next Steps

• The full results of the interim analysis will be presented at the ASCO Annual Meeting on June 2, 2024.
• The company plans to issue a press release on June 2, 2024 to announce the full results.
• Further investigation of the EZFB regimen is warranted.

Key Dates

Keywords

colorectal cancer, metastatic, etrumadenant, zimberelimab, FOLFOX, bevacizumab, regorafenib, clinical trial, PFS, OS, ARC-9, immunotherapy, chemotherapy